Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 517-523

  Peniston, John H ^a   Gold, Morris S ^b   Wieman, Matthew S ^c   Alwine, Lawrence K ^d  

^a Feasterville Family Health Care Center   (United States)

^b Novartis Consumer Health Inc   (United States)

^c ENDO PHARMACEUTICALS INC   (United States)

^d Downingtown Family Medicine   (United States)

Author keywords

Diclofenac; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Topical analgesic

Indexed keywords

DICLOFENAC; PARACETAMOL; PLACEBO;

ADULT; AGED; APPLICATION SITE DERMATITIS; ARTHRALGIA; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL STUDY; COMORBIDITY; CONTROLLED STUDY; CONTUSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFECTION; INFLUENZA; KNEE OSTEOARTHRITIS; LIMB PAIN; LONG TERM EXTENSION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NECK PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PAIN; PERIPHERAL EDEMA; PNEUMONIA; RHINOPHARYNGITIS; RISK FACTOR; SINUS CONGESTION; SINUSITIS; SORE THROAT; TOOTH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, CUTANEOUS; ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DICLOFENAC; FEMALE; GELS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OSTEOARTHRITIS;

EID: 84872290242     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S35416     Document Type: Article

References (30)

1. Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients. BMJ. 1995;310:817-818.
2. Zhang W, Moskowitz RW, Nuki G, etal. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-162.
3. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis. 2007;66:417-418.
4. Franceschi M, Di Mario F, Leandro G, Maggi S, Pilotto A. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol. 2009;23:839-848.
5. Richy F, Bruyere O, Ethgen O, etal. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63:759-766.
6. Antman EM, Bennett JS, Daugherty A, etal. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
7. Motsko SP, Rascati KL, Busti AJ, etal. Temporal relationship between use of NSAIDs, including selective COX-2inhibitors, and cardiovascular risk. Drug Saf. 2006;29:621-632.
8. Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther. 2004;11:124-129.
9. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45:531-539.
10. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106: 13S-24S.
11. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia RodriguezLA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006;92:1610-1615.
12. Zhang W, Doherty M, Leeb BF, etal. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:377-388.
13. Zhang W, Nuki G, Moskowitz RW, etal. OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476-499.
14. Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs. 2010;50:50-61.
15. Sandelin J, Harilainen A, Crone H, etal. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol. 1997;26:287-292.
16. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31:2002-2012.
17. Zacher J, Burger KF, Farber L. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Aktuelle Rheumatologie. 2001;26:7-14. German.
18. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143:238-245.
19. Altman RD, Dreiser RL, Fisher CL, etal. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:1991-1999.
20. Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed. 2010;38:19-28.
21. Barthel HR, Haselwood D, Longley S 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39:203-212.
22. Baraf HS, Gold MS, Petruschke RA, Wieman MS. Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Am J Geriatr Pharmacother. 2012;10:47-60.
23. Peniston JH, Gold MS, Alwine LK. An open-label, long-term safety and tolerability trial of diclofenac sodium 1% gel in patients with knee osteoarthritis. Phys Sportsmed. 2011;39:31-38.
24. Altman R, Alarcón G, Appelrouth D, etal. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33:1601-1610.
25. Dawson J, Linsell L, Zondervan K, etal. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford). 2004;43:497-504.
26. Rosamond W, Flegal K, Friday G, etal. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
27. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460-464.
28. Tulner LR, Frankfort SV, Gijsen GJ, etal. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25:343-355.
29. World Health Organozation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 1999.
30. Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med. 2009;121:9-20.